| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2025 ended Dec 31, 2024 | FY 2025 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 44.56B | 42.88B | 42.86B | 44.91B | 39.21B | 32.22B |
| Research and development | 1.40B | 1.39B | 1.34B | 1.47B | 1.41B | 1.18B |
| Selling, general and admin | 8.73B | 8.60B | 8.45B | 8.99B | 8.01B | 6.93B |
| Operating expenses | 36.81B | 35.54B | 36.00B | 36.52B | 29.18B | 24.42B |
| Operating income | 7.75B | 7.34B | 6.86B | 8.39B | 10.03B | 7.79B |
| EBITDA | 8.80B | 8.49B | 7.93B | 9.38B | 10.86B | 8.45B |
| Interest expense | 1.42B | 1.39B | 1.38B | 726.00M | 536.00M | 553.00M |
| Income before tax | 7.31B | 7.04B | 6.30B | 7.83B | 8.84B | 7.22B |
| Income tax | 547.00M | 657.00M | 284.00M | 703.00M | 1.11B | 850.00M |
| Net income | 6.72B | 6.34B | 5.96B | 6.96B | 7.73B | 6.38B |
| EPS | 17.77 | 16.58 | 15.52 | 17.75 | 19.62 | 16.09 |
| EPS (diluted) | 17.74 | 16.53 | 15.45 | 17.63 | 19.46 | 15.96 |
| Diluted shares | 378.00M | 383.00M | 388.00M | 394.00M | 397.00M | 399.00M |
| Dividends per share | 1.72 | 1.56 | 1.40 | 1.20 | 1.04 | 0.88 |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.